Evidence map›Paper›PMID 42358826›Full record

ArticleOncology research2026

Factors Affecting the Efficacy and Safety of First-Line Anti-PD-1 Therapy in Advanced Non-Small Cell Lung Cancer.

Zhen Wang, Qian Xie, Yu Luo, Chuan Li, Wenqiang Guan, Yanling Zhang, Jidong Miao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zhen WangDepartment of Oncology, Zigong Fourth People's Hospital, Ziliujing District, Zigong, China.
Qian XieSchool of Education and Sports, Sichuan Vocational College of Health and Rehabilitation, Yantian District, Zigong, China.
Yu LuoDepartment of Critical Care, Qingdao Municipal Hospital, Shinan District, Qingdao, China.
Chuan LiDepartment of Oncology, Zigong Fourth People's Hospital, Ziliujing District, Zigong, China.
Wenqiang GuanDepartment of Oncology, Zigong Fourth People's Hospital, Ziliujing District, Zigong, China.
Yanling ZhangDepartment of Respiratory and Critical Care Medicine, Qingdao Municipal Hospital, Qingdao University, Shinan District, Qingdao, China.
Jidong MiaoDepartment of Oncology, Zigong Fourth People's Hospital, Ziliujing District, Zigong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Carcinoma, Non-Small-Cell LungImmune Checkpoint InhibitorsLung NeoplasmsProgrammed Cell Death 1 ReceptorAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansMaleMiddle AgedNeoplasm StagingRetrospective StudiesTreatment OutcomeImmune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 ReceptorAdvanced non-small cell lung cancerimmune-related adverse eventsPD-1 inhibitorsprognosissafety

Identifiers

PMID42358826
PMCPMC13292038

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.